Lecanemab Treatment in a Specialty Memory Clinic. — ImportanceTwo monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events...

Evidence span

Lecanemab Treatment in a Specialty Memory Clinic. — ImportanceTwo monoclonal antibodies targeting amyloid plaques, lecanemab and donanemab, have received traditional US Food and Drug Administration (FDA) approval for the treatment of early symptomatic Alzheimer disease (AD). The most significant adverse events...

From Paczynski M et al. 2025, JAMA neurology

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Treatment Outcome; Retrospective Studies; Aged — JAMA neurology 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required